Carbamazepine-Induced Acute Alopecia Areata

Author(s):
Chaturbhuj Rathore, MD; Kalu Singh Rawat, MD; Sanjay Prakash, MD; Kaushik Rana, MD

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Corresponding Author:
Chaturbhuj Rathore
cbrathore@rediffmail.com

Affiliation Information for All Authors: 1. SBKS Medical Institute and Research Center, Sumandeeep Vidyapeeth, Vadodara, Gujarat, India

Contributions:
Chaturbhuj Rathore: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design
Kalu Singh Rawat: Major role in the acquisition of data
Sanjay Prakash: Drafting/revision of the manuscript for content, including medical writing for content
Kaushik Rana: Major role in the acquisition of data

Number of characters in title: 43
Abstract Word count: 0
Word count of main text: 93
References: 1
Figures: 1
Tables: 0
Neuroimage Legend Count: 41


Study Funding: The authors report no targeted funding

Disclosures: None of the authors report any disclosures.
18-year-old, previously healthy, male with recent onset nonlesional focal epilepsy developed alopecia areata after 3 days of starting carbamazepine at a dose of 200 mg daily (Figure; A). There were no skin rashes or systemic symptoms. Carbamazepine was switched to lacosamide. Hair regrowth was noted at 2 and 6 months of followup (Figure; B & C).

Drug induced alopecia areata is a rare disorder.\(^1\) Antiseizure medicines can cause generalized alopecia but not alopecia areata. This is a rare case of alopecia areata induced by carbamazepine, probably representing a restricted form of hypersensitivity reaction.
## Appendix 1: Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaturbhuj Rathore, MD</td>
<td>Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Vadodara, India</td>
<td>Conceived and designed the study; collected data; prepared the first draft</td>
</tr>
<tr>
<td>Kalu Singh Rawat, MD</td>
<td>Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Vadodara, India</td>
<td>Contributed to data collection; edited the final report for the intellectual content</td>
</tr>
<tr>
<td>Sanjay Prakash, MD</td>
<td>Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Vadodara, India</td>
<td>Contributed to data collection; edited the final report for the intellectual content</td>
</tr>
<tr>
<td>Kaushik Rana, MD</td>
<td>Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Vadodara, India</td>
<td>Contributed to data collection; edited the final report for the intellectual content</td>
</tr>
</tbody>
</table>
References


Figure title:

Carbamazepine induced alopecia areata

Alopecia areata after 3 days of starting 200 mg sustained release carbamazepine (A); Hair regrowth at 2 (B) and 6 months (C). Only one-third of the patients with drug induced alopecia areata have complete hair regrowth underlining the importance of early recognition.
Carbamazepine-Induced Acute Alopecia Areata
Chaturbhuj Rathore, Kalu Singh Rawat, Sanjay Prakash, et al.

Neurology published online June 18, 2021
DOI 10.1212/WNL.0000000000012387

This information is current as of June 18, 2021